Dear Editor,

We have read the case presentation of Shi et al. ([@B1]) with great interest. They report the clinical and radiological features of a 2019 novel coronavirus (COVID-19) patient presenting with hemoptysis. Serial computed tomography studies revealed the evolution of pulmonary involvement, and microbiological studies confirmed the diagnosis for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the exact cause and mechanism of hemoptysis in the patient remain to be explained. Hemoptysis is not a typical symptom of COVID-19. Large studies and case-series of COVID-19 have either not reported hemoptysis or have reported very low rates of 0.9--5% ([@B2][@B3][@B4]).

SARS-CoV-2 is known to cause a proinflammatory and hypercoagulable state with elevated levels of lactate dehydrogenase, D-dimer, C-reactive protein, ferritin, and interleukins ([@B5]). Data on thromboembolic complications of the disease are appearing, and there are increasing reports describing thromboembolic events complicating the COVID-19 disease ([@B6]). A study from the Netherlands investigated the high incidence of thrombotic complications among 184 COVID-19 patients in the intensive care unit ([@B7]). All patients received at least standard doses thromboprophylaxis and the cumulative incidence of the thrombotic complications was reported as 31%, with pulmonary embolism being the most frequent (n = 25, 81%).

While hemoptysis is a very rare presentation in COVID-19 patients, its incidence gets relatively higher reaching up to 13% in patients with pulmonary emboli ([@B8]). A very recent article reported a patient with SARS-CoV-2 presenting with hemoptysis ([@B9]). In addition to the findings of peripheral ground-glass opacities consistent with COVID-19 pneumonia, a computerized tomography angiography of the chest revealed bilateral segmental pulmonary emboli and an additional area of consolidation in the right lower lobe concerning for infarct.

COVID-19 patient may develop hemoptysis with or without pulmonary emboli; however the former is more likely. Moreover, attempts for delineation of mechanisms underlying this complication in COVID-19 can contribute to a better understanding. Therefore, we postulate that pulmonary emboli should be initially ruled out in all COVID-19 patients presenting with hemoptysis.
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To the Editor,

Thanks for your comments regarding our publication.

The most common clinical presentations of pulmonary embolism include dyspnea, chest pain, hemoptysis, and elevated level of D-dimer ([@BC1]). The 2019 novel coronavirus (COVID-19) patients with pulmonary embolism also presented with similar symptoms, such as worsening chest pain, shortness of breath, dyspnea, hemoptysis, and elevated D-dimer ([@BC2][@BC3][@BC4]). The case we reported did not show any of the symptoms except hemoptysis during the first week of admission. In addition, several initial D-dimer tests were negative, and the patient was found with no predisposing factors. So, pulmonary embolism was ruled out according to guidelines of pulmonary thromboembolism by the Chinese Medical Association ([@BC4]).

Furthermore, dyspnea and hemoptysis gradually disappeared after treatment with antivirals, anti-infection, and high flow oxygen therapy, and ground-glass opacities were cleared in the fourth chest CT. The diagnosis of pulmonary embolism was excluded again.
